Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06170190

A Multicentre,Study of IBI133 in Subjects WithUnresectable, Locally Advanced or Metastatic SolidTumours

A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Conditions Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions IBI133

Updated 5 times since 2024 Last updated: Nov 13, 2025 Started: Jan 16, 2024 Primary completion: Feb 19, 2025 Completion: Feb 19, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Locally Advanced Unresectable or Metastatic Solid Tumors and is currently completed. Innovent Biologics (Suzhou) Co. Ltd. leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE1/PHASE2

Status: Recruiting → Completed
Sep 2024 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2024 — Mar 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Innovent Biologics (Suzhou) Co. Ltd.

Data source: Innovent Biologics (Suzhou) Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Liverpool, Australia